Cutaneous side effects of doxycycline: a pediatric case series.
OBJECTIVE
Brucellosis is highly endemic in Turkey and doxycycline is commonly used for its treatment. The present study aimed at documenting the cutaneous side effects of doxycycline in pediatric brucellosis patients in Turkey.


METHODS
Pediatric patients with brucellosis that were treated between February 2014 and January 2016 were analyzed retrospectively, and those that developed doxycycline-related cutaneous side effects were identified. Demographic data, epidemiological history, physical examination findings, laboratory test results, anti-brucellosis treatment regimen, duration of follow up and outcome were recorded.


RESULTS
Among the 189 brucellosis patients, 141 treated with doxycycline plus rifampicin. Seven patients (5%) (two female and five male) developed doxycycline-related cutaneous side effects. Mean duration of treatment before the onset of cutaneous side effects was 9.5 weeks. Doxycycline therapy was continued in five of these patients and was changed in two patients. In the patients that continued to receive doxycycline the cutaneous side effects gradually improved.


CONCLUSIONS
Cutaneous side effects of doxycycline should always be a consideration, especially in regions in which brucellosis is endemic and doxycycline is commonly used to treat it.
a Department of Pediatric Infectious Disease , Yuzuncu Yil University, Medical Faculty , Van , Turkey.
Gulsum Iclal
GI
Bayhan
b Department of Pediatric Hematology , Yuzuncu Yil University, Medical Faculty , Van , Turkey , and.
Sinan
S
Akbayram
c Department of Dermatology , Yuzuncu Yil University, Medical Faculty , Van , Turkey.
Goknur
G
Ozaydin Yavuz
b Department of Pediatric Hematology , Yuzuncu Yil University, Medical Faculty , Van , Turkey , and.
Ahmet Fayik
AF
Oner
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002006:Brucellosis / Q000188:drug therapy* / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D004318:Doxycycline / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000009:adverse effects; D019353:Endemic Diseases; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D012189:Retrospective Studies; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use; D012867:Skin / Q000187:drug effects*; D013997:Time Factors; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects / Q000627:therapeutic use; D014421:Turkey / Q000453:epidemiology
D000900:Anti-Bacterial Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D004318:Doxycycline; D012293:Rifampin
Brucellosis; doxycycline; side effect; skin